With the first genetic therapy clinical trials for CF opening in the UK this year, we have created a new online information resource – which includes FAQs, video Q&As and a glossary. We talk to people from across the CF community about what this means to them.
To celebrate International Clinical Trials Day on 20 May, Georgia from our Clinical Trials Accelerator Platform (CTAP) central coordinating team reports back on a recent visit to the Bristol CF centre.
She met with the Clinical Trials teams in both the children’s and adults’ CF centres to find out what a typical day is like.
As part of our new programme of employment support for people with CF, Work Forwards, 39-year-old manager Alison Smith shares her journey into work and talks about how she manages her schedule alongside her CF.
This study aims to evaluate whether a new triple combination CFTR modulator treatment (VX-121/TEZ/D-IVA) is safe and effective in children with cystic fibrosis aged between 1 and 11 years. CFTR modulators help the faulty CFTR protein to function properly. The treatment is made up of three medications: VX-121, tezacaftor and deutivacaftor. Deutivacaftor is a slightly modified version of ivacaftor that is potentially more stable in the body. This means deutivacaftor can be taken once a day instead of twice a day. All participants will be give n an oral tablet of the treatment to take once a day. The researchers...